LUPRON DEPOT PED

Lupron Depot Ped Adverse Events Reported to the FDA Over Time

How are Lupron Depot Ped adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Lupron Depot Ped, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Lupron Depot Ped is flagged as the suspect drug causing the adverse event.

Most Common Lupron Depot Ped Adverse Events Reported to the FDA

What are the most common Lupron Depot Ped adverse events reported to the FDA?

Injection Site Pain	27 (4.1%)
Drug Dispensing Error	23 (3.5%)
Headache	21 (3.19%)
Incorrect Dose Administered	19 (2.89%)
Pyrexia	18 (2.74%)
Injection Site Abscess	17 (2.58%)
Weight Increased	15 (2.28%)
Injection Site Erythema	13 (1.98%)
Arthralgia	12 (1.82%)
Drug Ineffective	12 (1.82%)
Drug Dose Omission	11 (1.67%)
	Show More
Gait Disturbance	10 (1.52%)
Pain In Extremity	10 (1.52%)
Convulsion	8 (1.22%)
Dizziness	8 (1.22%)
Dyspnoea	8 (1.22%)
Injection Site Abscess Sterile	8 (1.22%)
Injection Site Reaction	8 (1.22%)
Pain	8 (1.22%)
Injection Site Nodule	7 (1.06%)
Injection Site Swelling	7 (1.06%)
Crying	6 (.91%)
Dysacusis	6 (.91%)
Hyperacusis	6 (.91%)
Nausea	6 (.91%)
Rash	6 (.91%)
Wrong Drug Administered	6 (.91%)
Diarrhoea	5 (.76%)
Hot Flush	5 (.76%)
Mood Swings	5 (.76%)
Overdose	5 (.76%)
Urticaria	5 (.76%)
Vomiting	5 (.76%)
Abasia	4 (.61%)
Breast Enlargement	4 (.61%)
Feeling Hot	4 (.61%)
Growth Accelerated	4 (.61%)
Hypersensitivity	4 (.61%)
Hypertension	4 (.61%)
Infection	4 (.61%)
Injection Site Discomfort	4 (.61%)
Mobility Decreased	4 (.61%)
Neuropathy Peripheral	4 (.61%)
Oedema Peripheral	4 (.61%)
Off Label Use	4 (.61%)
Abnormal Behaviour	3 (.46%)
Abscess	3 (.46%)
Balance Disorder	3 (.46%)
Body Height Increased	3 (.46%)
Csf Protein Increased	3 (.46%)
Death	3 (.46%)
Depression	3 (.46%)
Drug Effect Decreased	3 (.46%)
Drug Prescribing Error	3 (.46%)
Fall	3 (.46%)
Inappropriate Schedule Of Drug Admi...	3 (.46%)
Incorrect Drug Dosage Form Administ...	3 (.46%)
Injection Site Induration	3 (.46%)
Metrorrhagia	3 (.46%)
Muscle Spasms	3 (.46%)
Myalgia	3 (.46%)
Papilloedema	3 (.46%)
Personality Change	3 (.46%)
Rash Papular	3 (.46%)
Rash Pruritic	3 (.46%)
Urinary Tract Infection	3 (.46%)
Vaginal Haemorrhage	3 (.46%)
Viral Infection	3 (.46%)
Abdominal Pain	2 (.3%)
Acne	2 (.3%)
Aggression	2 (.3%)
Alopecia	2 (.3%)
Anger	2 (.3%)
Areflexia	2 (.3%)
Blood Testosterone Abnormal	2 (.3%)
Bone Cyst	2 (.3%)
C-reactive Protein Increased	2 (.3%)
Cauda Equina Syndrome	2 (.3%)
Chest Pain	2 (.3%)
Contusion	2 (.3%)
Cough	2 (.3%)
Demyelinating Polyneuropathy	2 (.3%)
Disorientation	2 (.3%)
Disturbance In Attention	2 (.3%)
Emotional Disorder	2 (.3%)
Fatigue	2 (.3%)
Feeling Abnormal	2 (.3%)
Generalised Erythema	2 (.3%)
Guillain-barre Syndrome	2 (.3%)
Hair Disorder	2 (.3%)
Ill-defined Disorder	2 (.3%)
Injection Site Haemorrhage	2 (.3%)
Injection Site Mass	2 (.3%)
Injection Site Pruritus	2 (.3%)
Injection Site Urticaria	2 (.3%)
Joint Swelling	2 (.3%)
Latent Tuberculosis	2 (.3%)
Limb Discomfort	2 (.3%)
Loss Of Consciousness	2 (.3%)
Malaise	2 (.3%)
Medication Error	2 (.3%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Lupron Depot Ped, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lupron Depot Ped is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Lupron Depot Ped

What are the most common Lupron Depot Ped adverse events reported to the FDA?

Administration Site Reactions	90 (13.68%)
Medication Errors	79 (12.01%)
Infections - Pathogen Unspecified	33 (5.02%)
Neurological	27 (4.1%)
Epidermal And Dermal Conditions	25 (3.8%)
Headaches	23 (3.5%)
Physical Examination Topics	20 (3.04%)
Musculoskeletal And Connective Tiss...	19 (2.89%)
Body Temperature Conditions	18 (2.74%)
Therapeutic And Nontherapeutic Effe...	17 (2.58%)
Gastrointestinal Signs	15 (2.28%)
	Show More
Joint	15 (2.28%)
Hearing	12 (1.82%)
Mood Disorders	12 (1.82%)
Respiratory	12 (1.82%)
Muscle	10 (1.52%)
Seizures	9 (1.37%)
Menstrual Cycle And Uterine Bleedin...	8 (1.22%)
Peripheral Neuropathies	8 (1.22%)
Injuries	7 (1.06%)
Skin Appendage Conditions	7 (1.06%)
Gastrointestinal Motility And Defec...	6 (.91%)
Personality Disorders	6 (.91%)
Angiedema And Urticaria	5 (.76%)
Bacterial Infectious	5 (.76%)
Breast	5 (.76%)
Procedural And Device Related Injur...	5 (.76%)
Vascular	5 (.76%)
Vulvovaginal Disorders	5 (.76%)
Allergic Conditions	4 (.61%)
Bone Disorders	4 (.61%)
Depressed Mood Disorders	4 (.61%)
Endocrine Investigations	4 (.61%)
Hypothalamus And Pituitary Gland	4 (.61%)
Therapeutic Procedures And Supporti...	4 (.61%)
Vascular Hypertensive	4 (.61%)
Bone And Joint Injuries	3 (.46%)
Dental And Gingival Conditions	3 (.46%)
Fatal Outcomes	3 (.46%)
Neurological, Special Senses And Ps...	3 (.46%)
Ocular Structural Change, Deposit A...	3 (.46%)
Psychiatric And Behavioural Symptom...	3 (.46%)
Sleep Disorders	3 (.46%)
Tissue	3 (.46%)
Viral Infectious	3 (.46%)
Deliria	2 (.3%)
Endocrine Disorders Of Gonadal Func...	2 (.3%)
Hematology Investigations	2 (.3%)
Mental Impairment	2 (.3%)
Microbiology And Serology	2 (.3%)
Movement Disorders	2 (.3%)
Mycobacterial Infectious	2 (.3%)
Nephropathies	2 (.3%)
Nervous System Neoplasms Malignant ...	2 (.3%)
Protein And Chemistry Analyses	2 (.3%)
Renal And Urinary Tract Investigati...	2 (.3%)
Spinal Cord And Nerve Root	2 (.3%)
White Blood Cell	2 (.3%)
Anxiety Disorders	1 (.15%)
Appetite And General Nutritional	1 (.15%)
Aural	1 (.15%)
Chemical Injury And Poisoning	1 (.15%)
Cognitive And Attention Disorders	1 (.15%)
Cornification And Dystrophic Skin	1 (.15%)
Eye	1 (.15%)
Glucose Metabolism Disorders	1 (.15%)
Hepatic And Hepatobiliary	1 (.15%)
Immune	1 (.15%)
Ocular Infections, Irritations And ...	1 (.15%)
Ocular Sensory Symptoms	1 (.15%)
Ovarian And Fallopian Tube	1 (.15%)
Pigmentation	1 (.15%)
Renal Disorders	1 (.15%)
Schizophrenia And Other Psychotic	1 (.15%)
Testicular And Epididymal	1 (.15%)
Tongue Conditions	1 (.15%)
Upper Respiratory Tract Disorders	1 (.15%)
Urinary Tract Signs	1 (.15%)
Uterine, Pelvic And Broad Ligament	1 (.15%)
Vascular Hemorrhagic	1 (.15%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Lupron Depot Ped, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lupron Depot Ped is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.